🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-524939-39-02
Authorised Phase II

The Danish Anorexia Nervosa Psilocybin RCT (DANP-RCT). A Randomised, Active-Placebo-Controlled, Triple-blind, Superiority Study of Psilocybin-Assisted Acceptance and Commitment Therapy (ACT) in the Treatment of Treatment-resistant Anorexia Nervosa.

2025-524939-39-02 · tracked via the Priya Life Science EU tracker
Sponsor
Slagelse Hospital
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Mental Disorders
Decision date
01/08/2026
Enrollment target
62
Sites
Denmark

Condition studied

Anorexia nervosa

Investigational medicinal product(s)

PEX010

Eligibility

Age group
18-64 years
Sex
Female

Primary endpoint

Baseline plus 10 weeks

Endpoint detail

Baseline plus 22 weeks

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524939-39-02 on CTIS ↗ ← All trials in the EU